Opioids pp 53-78 | Cite as

Use of Organ Systems for Opioid Bioassay

  • J. A. M. Smith
  • F. M. Leslie
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 104 / 1)


The fundamental principle of bioassay is that interaction of an agonist drug with a specific cellular receptor leads to the production of a biological response. Since this involves a physiological endpoint, receptors can be examined in their native, functional state. This contrasts to radioligand binding assays, which are often carried out under nonphysiological conditions, and can only provide information about the receptor ligand recognition site.


Opioid Receptor Opioid Peptide Opiate Receptor Opioid Agonist Agonist Potency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48–58Google Scholar
  2. Berti F, Bruno F, Omini C, Racagni G (1978) Genotype dependent response of morphine and methionine-enkephalin on the electrically induced contractions of the mouse vas deferens. Naunyn Schmiedebergs Arch Pharmacol 305: 5–8PubMedGoogle Scholar
  3. Bill D, Hartley JE, Stephens RJ, Thompson AM (1983) The antinociceptive activity of meptazinol depends on both opiate and cholinergic mechanisms. Br J Pharmacol 79: 191–199PubMedGoogle Scholar
  4. Birch PJ, Hayes AG, Sheehan MJ, Tyers MB (1987) Norbinaltorphimine: antagonist profile at K opioid receptors. Eur J Pharmacol 144: 405–408PubMedGoogle Scholar
  5. Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond [Biol] 220: 141–162Google Scholar
  6. Brantl V, Pfeiffer A, Herz A, Henschen A, Lottispeich F (1982) Antinociceptive properties of β-casomorphin analogs as compared to their affinities towards p, and 5 opiate receptor sites in brain and periphery. Peptides 3: 793PubMedGoogle Scholar
  7. Broccardo M, Erspamer V, Falconieri Erspamer G, Improta G, Linari G, Melchiorri P, Montecucchi PC (1981) Pharmacological data on demorphins, a new class of potent opioid peptides from amphibian skin. Br J Pharmacol 73: 625–631PubMedGoogle Scholar
  8. Bryan WM, Callahan JF, Codd EE, Lemieuxc, Moore ML, Schiller PW, Walker RF, Huffman WF (1989) Cyclic enkephalin analogues containing α-amino-β-mercapto-β, β-pentamethylenepropionic acid at positions 2 or 5. J Med Chem 32: 302–304PubMedGoogle Scholar
  9. Budai D, Duckies SP (1989) Opioid-induced prejunctional inhibition of vasoconstriction in the rabbit ear artery: alpha-2 adrenoceptor activation and external calcium. J Pharmacol Exp Ther 251 (2): 497–501PubMedGoogle Scholar
  10. Carroll JA, Shaw JS, Wickenden AD (1988) The physiological relevance of low agonist affinity binding at opioid μ-receptors. Br J Pharmacol 94: 625–631PubMedGoogle Scholar
  11. Chavkin C, Goldstein A (1981a) Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc Natl Acad Sci USA 78: 6543–6547PubMedGoogle Scholar
  12. Chavkin C, Goldstein A (1981b) Demonstration of a specific dynorphin receptor in guinea pig ileum myenteric plexus. Nature 291: 591–593PubMedGoogle Scholar
  13. Chavkin C, Goldstein A (1984) Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus. Proc Natl Acad Sci USA 81: 7253–7257PubMedGoogle Scholar
  14. Corbett AD, Paterson SJ, McKnight AT, Magan J, Kosterlitz HW (1982) Dynorphin (1–8) and dynorphin (1–9) are ligands for the K-subtype of opiate receptor. Nature 299: 79–81PubMedGoogle Scholar
  15. Corbett AD, Kosterlitz HW, McKnight AT, Paterson SJ, Robson LE (1985) Preincubation of guinea-pig myenteric plexus with β-funaltrexamine: discrepancy between binding assays and bioassays. Br J Pharmacol 85: 665–673PubMedGoogle Scholar
  16. Cotton R, Giles MG, Miller L, Shaw JS, Timms D (1984) ICI174864: a highly selective antagonist for the opioid δ-receptor. Eur J Pharmacol 97: 331–332PubMedGoogle Scholar
  17. Cowie AL, Kosterlitz HW, Watt AJ (1968) Mode of action of morphine-like drugs on autonomic neuroeffectors. Nature 220: 1040–1042PubMedGoogle Scholar
  18. Cowie AL, Kosterlitz HW, Waterfield AA (1979) Factors influencing the release of acetylcholine from the myenteric plexus of the ileum of the guinea-pig and rabbit. Br J Pharmacol 64: 565–580Google Scholar
  19. Cox BM (1988) Peripheral actions mediated by opioid receptors. In: Pasternak GW (ed) The opiate receptors. Humana, Clifton, p 357Google Scholar
  20. Cox BM, Chavkin C (1983) Comparison of dynorphin-selective kappa receptors in mouse vas deferens and guinea pig ileum. Mol Pharmacol 23: 36–43PubMedGoogle Scholar
  21. Cox BM, Padhya R (1977) Opiate binding and effect in ileum preparations from normal and morphine pretreated guinea-pigs. Br J Pharmacol 61: 271–278PubMedGoogle Scholar
  22. Cox BM, Weinstock M (1966) The effect of analgesic drugs on the release of acetylcholine from electrically stimulated guinea pig ileum. Br J Pharmacol 27: 81–92Google Scholar
  23. Creese I, Snyder SH (1975) Receptor binding and pharmacological activity of opiates in the guinea-pig intestine. J Pharmacol Exp Ther 194: 205–219PubMedGoogle Scholar
  24. Dissanayake VUK, Hunter JC, Hill RG, Hughes J (1990) Characterization of κ-opioid receptors in the guinea-pig ileum. Eur J Pharmacol 182: 73–82PubMedGoogle Scholar
  25. Dixon DM, Traynor JR (1990) Evidence that the agonist action of dynorphin A (1-8) in the guinea-pig myenteric plexus may be mediated partly through conversion to [Leu5]enkephalin. Br J Pharmacol 101: 674–678PubMedGoogle Scholar
  26. Dougall IG, Leff P (1987) Pharmacological analysis of the calcium-dependence of μ-receptor agonism. Br J Pharmacol 92: 723–731PubMedGoogle Scholar
  27. Furchgott RF (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res 3: 21Google Scholar
  28. Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds) Catecholamines. Springer, Berlin Heidelberg New York, p 283 (Handbook of experimental pharmacology, vol 33 )Google Scholar
  29. Galli A (1985) Inhibition of cholinesterases by the opioid analgesic meptazinol. Biochem Pharmacol 34: 1579–1581PubMedGoogle Scholar
  30. Garzon J, Schulz R, Herz A (1985) Evidence for the e-type of opioid receptor in the rat vas deferens. Mol Pharmacol 28: 1–9PubMedGoogle Scholar
  31. Gillan MGC, Kosterlitz HW, Magnan J (1981) Unexpected antagonism in the rat vas deferens by benzomorphans which are agonists in other pharmacological tests. Br J Pharmacol 72: 13–15PubMedGoogle Scholar
  32. Gintzler AR, Hyde D (1983) Unmasking myenteric delta receptors. Life Sci 33 [suppl 1]: 323–325PubMedGoogle Scholar
  33. Gintzler AR, Pasternak GW (1983) Multiple mu receptors: evidence for mu2 sites in the guinea pig ileum. Neurosci Lett 39: 51–56PubMedGoogle Scholar
  34. Goldstein A, James IF (1984) Site-directed alkylation of multiple opioid receptors. Mol Pharmacol 25: 343–348PubMedGoogle Scholar
  35. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L (1979) Dynorphin- (1–13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 76: 6666–6670PubMedGoogle Scholar
  36. Goodall J, Hughes IE, Mackay D (1986) Quantification of the actions of agonists that simultaneously act on a particular type of receptor and have separate functional interactant properties. Br J Pharmacol 88: 639–644PubMedGoogle Scholar
  37. Gyang EA, Kosterlitz HW (1966) Agonist and antagonist actions of morphine-like drugs on the guinea-pig isolated ileum. Br J Pharmacol 27: 514–527Google Scholar
  38. Hayes AG, Kelly A (1985) Profile of activity of K receptor agonists in the rabbit vas deferens. Eur J Pharmacol 110: 317–322PubMedGoogle Scholar
  39. Hayes AG, Sheehan MJ, Tyers MB (1985) Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens using β-FNA. Br J Pharmacol 86: 899–904PubMedGoogle Scholar
  40. Henderson G, Hughes J (1976) The effects of morphine on the release of noradrenaline from the mouse vas deferens. Br J Pharmacol 57: 551–557PubMedGoogle Scholar
  41. Hughes IE, Mackay D (1985) Quantification of the characteristics of antagonists exhibiting both competitive antagonism and functional interaction. Br J Pharmacol 85: 271–275PubMedGoogle Scholar
  42. Hughes J (1975) Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res 88: 195–306Google Scholar
  43. Hughes J (1981) Peripheral opiate receptor mechanisms. Trends Pharmacol Sci 2: 21–24Google Scholar
  44. Hughes J, Kosterlitz HW, Leslie FM (1975a) Effects of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Br J Pharmacol 53: 371–381Google Scholar
  45. Hughes J, Smith TW, Kosterlitz HW, Fothergill, LA, Morgan BA, Morris HR (1975b) Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258: 577–579PubMedGoogle Scholar
  46. Huidobro-Toro JP, Caturay EM, Ling N, Lee NM, Loh HH, Way EL (1982) Studies on the structual prerequisites for the activation of the P-endorphin receptor on the rat vas deferens. J Pharmacol Exp Ther 222: 262–269PubMedGoogle Scholar
  47. Hunter JC, Leighton GE, Meecham KG, Boyle S, Horwell DC, Rees DC, Hughes J (1990) CI-977, a novel and selective agonist for the κ-opioid receptor. Br J Pharmacol 101: 183–189PubMedGoogle Scholar
  48. Hurlbut DE, Evans CJ, Barchas JD, Leslie FM (1987) Pharmacological properties of a proenkephalin A-derived opioid peptide: BAM 18. Eur J Pharmacol 138: 359–366PubMedGoogle Scholar
  49. Hutchinson M, Kosterlitz HW, Leslie FM, Waterfield AA, Terenius L (1975) Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have a strong antinociceptive activity but do not substitute for morphine in the dependent monkey. Br J Pharmacol 55: 541–546PubMedGoogle Scholar
  50. Ivarsson M, Neil A (1989) Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum: a possible explanation for previous observations on incomplete opioid cross-tolerance. Pharmacol Toxicol 65: 368–371PubMedGoogle Scholar
  51. James IF, Fischli W, Goldstein A (1984) Opioid receptor selectivity of dynorphin gene products. J Pharmacol Exp Ther 228: 88–93PubMedGoogle Scholar
  52. Johnson SM, Fleming WW (1989) Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol Rev 41 (4): 435–488PubMedGoogle Scholar
  53. Kenakin TP (1984) The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev 36: 165–183PubMedGoogle Scholar
  54. Kosterlitz HW, Waterfield AA (1975a) An analysis of the phenomenon of acute tolerance to morphine in the guinea-pig isolated ileum. Br J Pharmacol 53: 131–138PubMedGoogle Scholar
  55. Kosterlitz HW, Waterfield AA (1975b) In vitro models in the study of structure-activity relationships of narcotic analgesics. Annu Rev Pharmacol 15: 29–47PubMedGoogle Scholar
  56. Kosterlitz HW, Watt A J (1968) Kinetic parameters of narcotic agonists and antagonists, with particular reference to Af-allylnoroxymorphone (naloxone). Br J Pharmacol 33: 266–276Google Scholar
  57. Kosterlitz HW, Leslie FM, Waterfield A A (1975) Rates of onset and offset of action of narcotic analgesics in isolated preparations. Eur J Pharmacol 32: 10–16PubMedGoogle Scholar
  58. Kuno Y, Aoki K, Kajiwara M, Ishii K, Oka T (1986) The relative potency of enkephalins and P-endorphin in guinea-pig ileum, mouse vas deferens and rat vas deferens after the administration of peptidase inhibitors. Jpn J Pharmacol 41: 273–281PubMedGoogle Scholar
  59. Lees GM, Kosterlitz HW, Waterfield AA (1972) Characteristics of morphine-sensitive release of neurotransmitter substances. In: Kosterlitz HW, Collier HO J, Villareal JE (eds) Agonist and antagonist actions of narcotic analgesic drugs. Macmillan, London, pp 142–152Google Scholar
  60. Leff P, Dougall IG (1989) Estimation of affinities and efficacies for κ-receptor agonists in the guinea-pig ileum. Br J Pharmacol 96: 702–706PubMedGoogle Scholar
  61. Lemaire S, Magnan J, Regoli D (1978) Rat vas deferens a specific bioassay for endogenous opioid peptides. Br J Pharmacol 64: 327–329PubMedGoogle Scholar
  62. Leslie FM (1977) Opiate receptor mechanisms: an in vitro analysis. PhD thesis, University of Aberdeen, Great Britain Leslie FM (1987) Methods used for the study of opioid receptors. Pharmacol Rev 39 (3): 197–249Google Scholar
  63. Leslie FM, Goldstein A (1982) Degradation of dynorphin (1–13) by membrane- bound rat brain enzymes. Neuropeptides 2: 185–196Google Scholar
  64. Leslie FM, Chavkin C, Cox BM (1980) Opioid binding properties of brain and peripheral tissues: evidence for heterogeneity in opioid ligand binding sites. J Pharmacol Exp Ther 214: 395–402PubMedGoogle Scholar
  65. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature 267: 495–499PubMedGoogle Scholar
  66. McKnight AT, Corbett AD, Kosterlitz HW (1983) Increase in potencies of opioid peptides after peptidase inhibition. Eur J Pharmacol 86: 393–402PubMedGoogle Scholar
  67. McKnight AT, Corbett AD, Marcoli M, Kosterlitz HW (1985) The opioid receptors in the hamster vas deferens are of the δ-type. Neuropharmacology 24: 1011–1017PubMedGoogle Scholar
  68. Miller L, Ranee MJ, Shaw JS, Traynor JR (1985) Conversion of dynorphin-(1–9) to [Leu5]enkephalin by the mouse vas deferens in vitro. Eur J Pharmacol 116: 159–163PubMedGoogle Scholar
  69. Miller L, Shaw JS, Whiting EM (1986) The contribution of intrinsic activity to the action of opioids in vitro. Br J Pharmacol 87: 595–601PubMedGoogle Scholar
  70. Nicolaou N, Zioudrou C (1985) The effects of calcium on the responses to opioid peptides and morphine in the rat vas deferens. Communication to the International Narcotics Research Conference Abstr Handbook p 160Google Scholar
  71. Oka T, Negishi K, Suda M, Matsumiya T, Inazu T, Masaaki U (1980) Rabbit vas deferens: a specific bioassay for opioid K-receptor agonists. Eur J Pharmacol 73: 235–236Google Scholar
  72. Opmeer FA, van Ree JM (1979) Competitive antagonism of morphine action in vitro by calcium. Eur J Pharmacol 53: 395–397PubMedGoogle Scholar
  73. Pasternak GW, Goodman R, Snyder SH (1975) An endogenous morphine-like factor in mammalian brain. Life Sci 16: 1765–1769PubMedGoogle Scholar
  74. Paton WDM (1957) The action of morphine and related substances on contraction and on acetylcholine output of coaxially stimulated guinea-pig ileum. Br J Pharmacol Chemother 12: 119–127PubMedGoogle Scholar
  75. Paton WDM, Zar MA (1968) The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle fibres. J Physiol (Lond) 194: 13–33Google Scholar
  76. Porreca F, Burks TF (1983) Affinity of normorphine for its pharmacologic receptor in the naive and morphine-tolerant guinea-pig isolated ileum. J Pharmacol Exp Ther 225: 688–693PubMedGoogle Scholar
  77. Porreca F, LoPresti D, Ward SJ (1990) Opioid agonist affinity in the guinea-pig ileum and mouse vas deferens. Eur J Pharmacol 179: 129–139PubMedGoogle Scholar
  78. Portoghese PS, Sultana M, Takemori AE (1990) Design of peptidomimetic & opioid receptor antagonists using the message-address concept. J Med Chemistry 33: 1714–1720Google Scholar
  79. Raffa RB, Vaught JL, Porreca F (1989) Can equal pA2 values be compatible with receptor differences? Trends Pharmacol Sci 10: 183–185PubMedGoogle Scholar
  80. Rang HP (1964) Stimulant actions of volatile anaesthetics on smooth muscle. Br J Pharmacol 22: 356–362Google Scholar
  81. Rothman RB, Bykov V, de Costa BR, Jacobson AE, Rice KC, Brady L (1990) Interaction of endogneous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides 11: 311–331Google Scholar
  82. Sayre LM, Portoghese PS, Takemori AE (1983a) Difference between μ-receptors in the guinea pig ileum and the mouse vas deferens. Eur J Pharmacol 90: 159–160PubMedGoogle Scholar
  83. Sayre LM, Portoghese PS, Takemori AE (1983b) Alkylation of opioid receptor subtypes by α-chlornaltrexamine produces concurrent irreversible agonistic and irreversible antagonistic activities. J Med Chem 26: 503–506PubMedGoogle Scholar
  84. Schild HO (1957) Drug antagonism and pAx. Pharmacol Rev 9: 242–246PubMedGoogle Scholar
  85. Schiller PW, DiMaio J (1982) Opiate receptor subclasses differ in their conformational requirements. Nature 297: 74–76PubMedGoogle Scholar
  86. Schulz R, Faase M, Wüster M, Herz A (1979) Selective receptors for beta-endorphin on the rat vas deferens. Life Sci 24: 843–850PubMedGoogle Scholar
  87. Schulz R, Wüster M, Herz A (1981a) Pharmacological characterisation of the epsilon opiate receptor. J Pharmacol Exp Ther 216: 604–606PubMedGoogle Scholar
  88. Schulz R, Wüster M, Rubini P, Herz A (1981b) Functional opiate receptors in the guinea-pig ileum: their differentiation by means of selective tolerance development. J Pharmacol Exp Ther 219: 547–550PubMedGoogle Scholar
  89. Sheehan MJ, Hayes AG, Tyers MB (1986a) Irreversible selective blockade of κ-opioid receptors in the guinea-pig ileum. Eur J Pharmacol 129: 19–24PubMedGoogle Scholar
  90. Sheehan MJ, Hayes AG, Tyers MB (1986b) Pharmacology of δ-opioid receptors in the hamster vas deferens. Eur J Pharmacol 130: 57–64PubMedGoogle Scholar
  91. Sheehan MJ, Hayes AG, Tyers MB (1988) Lack of evidence for ε-opioid receptors in the rat vas deferens. Eur J Pharmacol 154: 237–245PubMedGoogle Scholar
  92. Shimohigashi Y, Costa T, Pfeiffer A, Herz A, Kimura H, Stammer CH (1987) ΔEPhe4-enkephalin analogs. Delta receptors in rat brain are different from those in the mouse vas deferens. FEBS Lett 222: 71–74Google Scholar
  93. Shook JE, Kazmierski W, Wire WS, Lemcke PK, Hruby VJ, Burks TF (1988) Opioid receptor selectivity of β-endorphin in vitro and in vivo: mu, delta and epsilon receptors. J Pharmacol Exp Ther 246: 1018–1025PubMedGoogle Scholar
  94. Smith CFC (1984) Morphine, but not diacetyl morphine (heroin), possesses opiate antagonist activity in the mouse vas deferens. Neuropeptides 5: 173–176PubMedGoogle Scholar
  95. Smith CFC, Carter A (1986) Delta receptors in the rat vas deferens. Arch Int Pharmacodyn Ther 284: 181–192PubMedGoogle Scholar
  96. Smith CFC, Ranee MJ (1983) Opiate receptors in the rat vas deferens. Life Sci 33 [Suppl l]: 327–330PubMedGoogle Scholar
  97. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol 11: 379–393Google Scholar
  98. Takemori AE, Portoghese PS (1984) Comparitive antagonism by naltrexone and naloxone of μ, κ, and δ agonists. Eur J Pharmacol 104: 101–104PubMedGoogle Scholar
  99. Takemori AE, Portoghese PS (1985) Receptors for opioid peptides in the guinea-pig ileum. J Pharmacol Exp Ther 235: 389–235PubMedGoogle Scholar
  100. Takemori AE, Ikeda M, Portoghese PS (1986) The μ, κ, and δ properties of various opioid agonists. Eur J Pharmacol 123: 357–361PubMedGoogle Scholar
  101. Terenius L, Wahlstrom A (1975) Search for an endogenous ligand for the opiate receptor. Acta Physiol Scand 94: 74–81PubMedGoogle Scholar
  102. Trendelenburg P (1917) Physiologische und pharmakologische Versuche über die Dünndarmperistaltik. Naunyn Schmeidebergs Arch Exp Pathol Pharmakol 81: 55–129Google Scholar
  103. Vaughn LK, Wire WS, Davis P, Shimohigashi Y, Toth G, Knapp RJ, Hruby VJ, Burks TF, Yamamura HI (1990) Differentiation between rat brain and mouse vas deferens δ opioid receptors. Eur J Pharmacol 177: 99–101PubMedGoogle Scholar
  104. Verlinde C, de Ranter C (1988) Assessment of the kappa-opioid activity of a series of 6, 7-benzomorphans in the rabbit vas deferens. Eur J Pharmacol 153: 83–87Google Scholar
  105. Walker JM, Moises HC, Coy DH, Baldrighi G, Akil H (1982) Nonopiate effects of dynorphin and destyr dynorphin. Science 218: 1136–1138PubMedGoogle Scholar
  106. Ward SJ, LoPresti D, James DW (1986) Activity of mu- and delta-selective opioid agonists in the guinea pig ileum preparation: differentiation into peptide and nonpeptide classes with P-funaltrexamine. J Pharmacol Exp Ther 238: 625–631PubMedGoogle Scholar
  107. Waterfield AA, Lord J AH, Hughes J, Kosterlitz HW (1978) Differences in the inhibitory effects of normorphine and opioid peptides on the responses of the vasa deferentia of two strains of mice. Eur J Pharmacol 47: 249–250PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • J. A. M. Smith
  • F. M. Leslie

There are no affiliations available

Personalised recommendations